Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Director Andrew D. Goldberg Purchases 1,000 Shares
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) Director Andrew D. Goldberg acquired 1,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $18.96 per share, with a total value of $18,960.00. Following the completion of the purchase, the director now directly owns 3,000 shares in the company, valued at $56,880. The purchase was disclosed in a filing with the SEC, which is available at this link.
Tarsus Pharmaceuticals Price Performance
TARS stock traded up $0.17 on Tuesday, reaching $19.15. The company had a trading volume of 692,112 shares, compared to its average volume of 326,241. The company has a market cap of $633.87 million, a P/E ratio of -5.12 and a beta of 0.86. Tarsus Pharmaceuticals, Inc. has a 1 year low of $11.33 and a 1 year high of $25.25. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.15 and a current ratio of 11.15. The company’s fifty day moving average is $16.07 and its 200 day moving average is $17.19.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.12. The firm had revenue of $1.87 million during the quarter, compared to analyst estimates of $0.72 million. On average, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.86 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada lifted its stake in Tarsus Pharmaceuticals by 122.0% during the second quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock valued at $50,000 after buying an additional 1,548 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Tarsus Pharmaceuticals by 310.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,736 shares of the company’s stock valued at $66,000 after purchasing an additional 2,825 shares in the last quarter. UBS Group AG boosted its stake in shares of Tarsus Pharmaceuticals by 37.0% during the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after acquiring an additional 1,142 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tarsus Pharmaceuticals by 65.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after buying an additional 2,092 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $94,000. Institutional investors and hedge funds own 70.02% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have weighed in on TARS. The Goldman Sachs Group started coverage on Tarsus Pharmaceuticals in a research report on Monday, November 20th. They set a “neutral” rating and a $19.00 target price for the company. HC Wainwright upped their target price on Tarsus Pharmaceuticals from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. Finally, Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $49.00 and gave the company a “buy” rating in a report on Monday, September 11th.
View Our Latest Report on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Company Profile (Get Free Report)
Tarsus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
NASDAQ: TARS” width=”650″ height=”350″ loading=”lazy”>
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tarsus Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tarsus Pharmaceuticals wasn’t on the list.
While Tarsus Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Which stocks are major institutional investors including hedge funds and endowments buying in today’s market? Click the link below and we’ll send you MarketBeat’s list of thirteen stocks that institutional investors are buying up as quickly as they can.